1. Discovery of AZD4831, a mechanism-based irreversible inhibitor of myeloperoxidase, as a potential treatment for heart failure with preserved ejection fraction;Inghardt;J Med Chem,2022
2. Early clinical experience with AZD4831, a novel myeloperoxidase inhibitor, developed for patients with heart failure with preserved ejection fraction;Nelander;Clin Transl Sci,2021
3. Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteers;Gan;Br J Clin Pharmacol,2019
4. Rationale and design of ENDEAVOR: a sequential phase 2b–3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction;Lund;Eur J Heart Fail,2023
5. Myeloperoxidase inhibitor AZD4831 target engagement and safety in a phase 2a study in patients with heart failure with preserved ejection fraction (SATELLITE);Lam;Eur J Heart Fail,2021